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Natural killer (NK) cells are cytotoxic lymphocytes that
play an important role in host immune responses to viruses,
parasites, intracellular bacteria, and tumor cells (Table 1).
They are also believed to be involved in graft-versus-host
disease (GVHD) and graft rejection after stem cell trans-
plantation. Natural killer cells constitute about 10% of all
blood lymphocytes. In contrast to cytotoxic T lymphocytes,
NK cells kill virus infected and malignant cells without prior
priming [1,2]. Killing of targets can occur through various
pathways (Table 2), although the granzyme-mediated path-
way is predominant [3]. When NK cells become activated
by cytokines, ie, by interf e ron (IFN)-γ, interleukin (IL)-2,
IL-12, IL-15, or IL-18, their number and cytotoxic activity
i n c rease and they kill a broader spectrum of targets. Acti-
vated NK cells have historically been designated lym-
phokine-activated killer (LAK) cells. Most investigators,
however, prefer the term activated NK (ANK) cells because
cytokines other than those produced by lymphocytes (ie,
I L -12 produced by monocytes) can also activate NK cells.
Although it is largely unknown why these activated NK cells
can kill targets that are generally not affected by NK cells,
such as Daudi or Jurkat lymphoma cell lines, recent data
suggest that the cytokine environment can induce specific
molecules on both NK as well as target cells to support cell
adhesion and to mediate cytolysis of NK cell–resistant tar-
gets [4]. Cantoni et al. [5] have shown that NKp44, a trig-
gering receptor involved in tumor cell lysine, is expressed on
ANK cells but not on NK cells. 
NK cells interact with target cells through diff e re n t
receptor stru c t u res. Most NK/ANK cells express the Fcγ
receptor CD16, which upon binding to the Fc component
of the immunoglobulin molecule activates NK-cell cytolytic
activity (antibody dependent cellular cytotoxicity, ADCC),
thus making cells and antibodies bound to their surface tar-
gets for NK cell killing. 
With respect to allogeneic stem cell transplantation,
the interaction of NK/ANK cells with major histocom-
patibility complex (MHC) antigens has become re l e v a n t .
In contrast to the “human leukocyte antigen (HLA)
re s t r i ction” of T-lymphocyte–mediated killing, NK cell
function is regulated by a balance of re g u l a t o ry activating
and inhibitory surface molecules that interact with specific
HLA molecules on the target cells. The recognition by
NK cells of “missing self” on target cells has become the
focus of intense re s e a rch. Under physiological circ u m-
stances, the inhibitory receptors on NK cells are activated
by recognition of intact (self) HLA class I antigens. Con-
v e r s e l y, mutated, missing, or altered HLA molecules will
trigger activation of NK cells. The generation of an
i n h i b i t o ry signal involves a re p e rt o i re of diverse members
of the killer cell inhibitory receptor (KIR) family and the
NKG2/CD94 family of molecules (Figure 1). Several dif-
f e rent KIR molecules have been cloned, and their interac-
tion with various class I antigens is unfolding [6]. The
ligand binding domain of KIR receptors consists of 2 to 3
extracellular immunoglobin domains. For inhibitory KIRs,
the signal transduction unit has a long cytoplasmic “tail”
that contains an immunoreceptor tyrosine-based inhibitory
motif (ITIM). If the tail is truncated and the ITIM is not
p resent, these receptors can act as killer cell–activating
receptors (KAR) through interaction with DAP 12, an
adapter protein with an immunoreceptor tyro s i n e – b a s e d
activating motive [7]. 
Although HLA molecules on target cells have re c e n t l y
been at the center of attention in terms of regulation of NK
activity, members of the B7 family (CD80) of co-stimulatory
molecules also regulate NK cell function [8]. 
When B7-1 is expressed on an otherwise poorly immuno-
geneic murine carcinoma cell line, NK-mediated cytotoxic-
ity is enhanced and tumor growth is inhibited [9]. Because
NK cells do not express CD40L or CD28, other B7 ligands
a re presumed to be involved in this interaction. Lysis of
autologous targets such as monocytes, macrophages, and
dendritic cells by NK cells may also occur through this
mechanism, which is believed to be relevant in the self-reg-
ulation of immune responses [10]. 
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F i n a l l y, adhesion molecules are essential for the initial
conjugate formation between NK and target cells. Blocking
of LFA-1 or ICAM-1 can lead to complete loss of NK/ANK
cell killing [4,11]. The same has been shown for CD44 on
ANK cells that bind to hyaluronic acid on tumor cells [12].
NK CELL RECOVERY AFTER AUTOLOGOUS AND
ALLOGENEIC STEM CELL TRANSPLANTATION
In healthy individuals, fresh bone marrow (BM) has no
or only minimal NK cell activity, whereas blood NK cells
show spontaneous killing of K562 cells. However, after
incubation with IL-2 for a few days, ANK cell–mediated
cytotoxicty of BM is significantly higher than that of
I L -2–activated blood lymphocytes [13]. 
Because of their large granular morphology, NK cells are
the first cells to recover after autologous or allogeneic BM or
peripheral blood stem cell (PBSC) transplantation (generally
about 3-4 days earlier than granulocytes or monocytes)
[ 1 4 -18]. These regenerating NK cells are of donor origin
[19]. Early NK cells are CD56 bright positive and CD3 nega-
tive, do not carry the Fc receptor CD16, have a higher pro l i f-
erative capacity, and display greater cytotoxicity than CD56
dim positive NK cells [20]. Three to 6 weeks after both autol-
ogous and allogeneic BM transplantation, the number and
the cytotoxic capacity of NK/ANK cells are completely nor-
mal, as measured by chromium release assay and pro d u c t i o n
of IFN-γ [21]. Such an early normalization of NK-cell func-
tion does not occur in patients recovering from the effects of
chemotherapy without stem cell support [21]. 
Depletion of T cells from donor marrow does not affect
the timely NK/ANK cell re c o v e ry posttransplant [22,23]
even if a T-depletion method is employed that also removes
m a t u re NK cells. After E-rosetting of the donor marro w
with sheep red blood cell treatment (which removes CD2-
positive NK cells), NK cell recovery still occurs early after
transplant [24,25]. Similar observations have been made
after ex vivo T-cell depletion with Campath 1 antibody,
which also removes CD52 positive NK cells from BM.
H o w e v e r, if the antibody is given posttransplant, it may
deplete newly produced NK cells, which could diminish
graft-versus-tumor (GvT) effects [26]. Recovery of NK-cell
numbers after transplantation of CD34-selected BM or
PBSC is also rapid [27].
C o l l e c t i v e l y, these studies suggest that the diff e re n t i a-
tion of NK cells from BM progenitor cells occurs rapidly
without restriction or thymic involvement [28,29]. It is
speculated that the cytokine environment posttransplant
favors NK cell progenitor cell growth and diff e re n t i a t i o n .
Both c-kit ligand and flt3 ligand enhance the expansion of
NK cell progenitors in the presence of IL-15, which is pro-
duced by marrow stroma [30]. 
After infusion of mafosfamide-purged autologous BM,
cytotoxicity of blood NK cells is reported to be significantly
higher than before transplant [31]. This positive effect of
chemical purging was detected in patients with acute myel-
ogenous leukemia (AML) and non-Hodgkin’s lymphoma
(NHL) but not with acute lymphoblastic leukemia (ALL).
Unfortunately, each disease category studied included only a
few patients, making it difficult to draw more general con-
clusions from this observation. Because a control group with
“no purging-cryopreservation only” was not included, it has
not been ruled out that the cryopreservation procedure itself
may have caused the stimulatory effect on NK-cell function. 
Immunosuppressive agents administered after transplan-
tation are known to impede lymphocyte function. Cyclo-
sporine does not affect NK or ANK cell function, whereas
azathioprine does so in a dose-dependent fashion, possibly
because of a numerical decrease of NK cells [32].
Because NK cells recover from progenitor cells post-
transplant, the number and function of NK cells in the
l e u k a p h e resis product is irrelevant, although a number of
studies have measured NK cell numbers and their function
in these collections [33-35]. Treatment of allogeneic donors
with G-CSF diminishes NK cell numbers and their func-
tion in the leukapheresis product. Still, re c o v e ry of NK
cells occurs early after allogeneic PBSC transplantation
[36]. Likewise, autologous recipients of PBSC that were
collected after mobilization with granulocyte colony-stimu-
lating factor (G-CSF) or granulocyte-macrophage colony
stimulating factor (GM-CSF) have the same swift NK cell
re c o v e ry as patients after autologous BM transplantation
[16,37,38]. Again, results on NK cells in stem cells collec-
tions, such as those by Verbik et al. [35] showing that PBSC
collections after priming with GM-CSF had the highest
yield of ANK precursor cells in the first 3 collections,
appear to bear no clinical implications. It seems to be more
relevant to look at what G-CSF or GM-CSF do in re g a rd
to the function of NK cells when given posttransplant.
G -CSF is known to down-regulate allogeneic T cell
responses through inhibition of tumor necrosis factor
( T N F ) -α p roduction, which pre f e rentially supports the dif-
f e rentiation of Th1 cells [39]. G-CSF given posttransplant
does not seem to affect NK cell re c o v e ry or function.
R i c h a rd et al. [40] re p o rted that patients receiving GM-
CSF (at 5 µg/kg per day) after autologous BM transplanta-
Table 1. What Are Natural Killer Cells?
Third subset of lymphocytes (in addition to T and B cells)
Independent of V(D)J recombination and receptor
Kill virus-infected and transformed cells
Activity without the need for priming
Important regulatory function (production of cytokines)
Express many different activating receptors
Kill MHC class I negative cells
Express inhibitory receptors specific for class I 
Table 2. Cytotoxic Mechanisms of Natural Killer Cells
Rapid 
Perforin and Granzyme (induces DNA fragmentation)
FasL binding to Fas on targets
Delayed
Tumor necrosis factor 
Nitric oxide
92
tion for AML had a higher cytolytic activity of blood ANK
than historical controls not treated with GM-CSF. None of
the patients receiving GM-CSF posttransplant who had an
ANK activity >20% relapsed, whereas 6 out of 9 patients
with <20% ANK activity did.
The number of CD56+ NK cells in blood of patients
after transplantation can be significantly expanded post-
transplant when IL-2 is given. Whereas relatively high doses
are necessary to expand T cells through stimulation of the
l o w - a ffinity IL-2 receptor (p55) expressed on T cells, low
doses of IL-2 given over a prolonged period of time will
expand NK cells through stimulation of the constitutively
expressed intermediate affinity IL-2 receptor (p75) [41]. NK
cells post–autologous PBSC transplantation can be re a d i l y
activated by IL-2 to even higher activity than after autolo-
gous or allogeneic BM transplantation [42]. Interleukin-12
seems to be even more potent than IL-2 in activating NK
cells in PBSC [43]. Cytokine treatment with IL-2 and/or
IL-12 may thus be an effective way to activate LAK precur-
sors after autologous PBSC transplantation and induce or
augment GvT effects in selected diseases.
NK CELLS IN CORD BLOOD
The cytotoxicity of fresh, nonstimulated cord blood
NK cells is significantly lower than that of blood NK
cells. H o w e v e r, when cord blood is incubated with IL-2,
NK cytotoxicty can be raised to the same level as that of
I L -2–stimulated blood NK cells [44,45]. Another study con-
firmed that NK cells in cord blood are functionally and phe-
notypically immature but are capable of maturation after
exposure to cytokines [46]. Observations by Lee et al. [47]
suggest that the immaturity of cord blood NK cells may at
least in part be because of the reduced production of IL-12
by cord blood mononuclear cells.
ARE NK CELLS INVOLVED IN GVHD?
It is generally accepted that GVHD is initiated by T
lymphocytes that recognize diff e rences in the expression of
MHC antigens and/or minor-histocompatibility antigens.
Unlike T lymphocytes, NK cells are at most contributers,
which on their own do not cause GVHD. T cells may re c ru i t
donor NK cells that may further stimulate the immune
response through cytokine release and possibly contribute to
tissue damage through production of infla mm a t o ry cytokines
and nitric oxide [48-50]. Depletion of T cells with an anti-
CD3 antibody [51] or a combination of anti-CD6 and anti-
CD8 [22] monoclonal antibodies can effectively pre v e n t
GVHD, despite the presence of NK cells in the graft.
Activated NK cells produce cytokines (such as IFN-γ) that
can maintain monocyte activation and lead to release of T N F -α
into the circulation. TNF-α is believed to be one of the cen-
tral cytokines in the cascade of GVHD events [52]. The pat-
t e rn of IFN-γ– t r i g g e red cytokines will also lead to clonal
expansion of Th1 cells that are predominant in GVHD. Stud-
ies in mice have shown that depletion of NK cells re d u c e s
I F N -γ levels and protects recipents from the sensitivity to
endotoxin seen in mice with acute GVHD [53]. These mice do
not secrete TNF-α into their serum when injected with LPS.
Viral infections can lead to activation of NK cells and a subse-
quent increase in INF-γ p roduction. It is speculative whether
Figure 1. Schematic presentation of natural killer (NK) receptor structures. Killer cell inhibitory receptors (KIR) belong to the immunoglobulin (Ig) type super-
family. If the immunoreceptor tyrosine–based inhibitory motif (ITIM) is present, the receptor inhibits NK cell function, whereas the receptor causes the NK cells to
be activated if ITIM is not present. NKG2 associates with CD94 and, through interaction with human leukocyte antigen (HLA)-E on target cells, inhibits NK cell
function. Reactive with HLA-A, HLA-B, and ligands, some KIR members have 2 Ig domains (KIR 2D) and others have 3 Ig domains (KIR 3D). KIR members
vary also in the length of the cytoplasmatic tail.
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this reaction is a main factor responsible for the exacerbation of
GVHD that frequently occurs with a viral infection. 
In murine models, infusion of allogeneic NK/ANK cells
does not cause GVHD compared to infusion of cytotoxic lym-
phocytes obtained from spleen cells co-cultured with re c i p i e n t
spleen cells [54]. The studies by Asai et al. [55] go one step
f u rt h e r, showing in a murine transplant model (BALB/C into
C57BL6) that adoptively transferred donor NK cells can p re-
vent GVHD, an effect that was abrogated when mice were
given anti-TGF beta. Observations in patients after hap-
loidentical transplantation also confirm that alloreactive NK
cells occur at high frequency in recipients who lacked the
class I molecules re q u i red to inhibit donor NK-KIR mole-
cules [56]. However, the donor-derived NK cell response did
not cause any GVHD in transplant re c i p i e n t s .
ARE NK CELLS INVOLVED IN GRAFT REJECTION?
D i rect evidence for a contribution of NK cells to the
rejection of human stem cell grafts has not been pro v i d e d ,
although a role is suspected [57]. The phenomenon of
“hybrid resistance” in mice is frequently quoted as evidence
for NK-cell–mediated rejection. In hybrid resistance, NK
cells from an irradiated F1 hybrid between two H-2 dis-
parate parents reject a BM graft from either parent, as the
graft lacks self-MHC class I molecules [58]. Hybrid re s i s-
tance is restricted to certain murine strain combinations and
occurs only when limited numbers of donor marrow cells are
given. Hybrid resistance can also be overcome if re c i p i e n t s
a re treated with cyclophosphamide, radiation, or antithymo-
cyte globulin, although its relevance in human transplants is
c o n t roversial. Hybrid resistance mediated by NK cells may
well play a role in the failure of children with severe com-
bined immunodeficiency (SCID) to engraft following
t r a n splants of unmodified, unrelated marrow grafts and
T-cell–depleted marrow from haplotype disparate or fetal
tissue transplants from fully matched allogeneic donors.
Some studies endorse the notion that NK cells support
engraftment [59]. In mice, administration of LAK cells early
after allogeneic BM transplant led to faster engraftment and
less graft failure, especially after T-cell–depleted transplan-
tation. Although veto and suppressor activities have been
discussed [60], it is likely that such a graft-enhancing poten-
tial is mediated by hematopoietically active cytokines such as
IL-3 and GM-CSF, which are produced and released by
ANK/LAK cells. 
Infiltrates with NK cells can be found in re j e c t e d
murine solid organ grafts. Surprisingly, a study by Zijlstra
et al. showed that depletion of NK cells had no impact on
the incidence of organ rejection [61]. In contrast to allo-
transplant models, the involvement of NK cells in the
rejection of xenografts seems to be better documented
[62,63], possibly because no MHC class I molecules are
recognized by inhibitory receptors on NK cells. Host NK
cells have to be depleted for rat BM to engraft in mice [64].
It has been suggested that in xenotransplantation, the
hyperacute rejection mediated by anti-gal xeno-re a c t i v e
natural antibodies is so dominant that it generally masks
any NK-cell–mediated re ject ion [65] and that NK-
cell–mediated rejection may become relevant if the anti-gal
response is abrogated [66]. 
EX VIVO EXPANSION OF NK/ANK CELLS
In order to use NK or ANK cells for clinical applica-
tions, certain specifics in re g a rd to expansion and cry o p re s e r-
vation need to be considered. The expansion of ANK cells
f rom blood is cumbersome and expensive. It involves leuka-
p h e resis of the patient after administration of high doses of
IL-2, followed by ex vivo expansion of NK cells over several
days. Infusion of these cells re q u i res injections of IL-2 to
maintain in vivo activity of ANK cells. The high doses of
I L -2 can cause significant side effects, and the high costs
make this pro c e d u re difficult to justify [67]. If no IL-2 is
a d m i n i s t e red prior to leukapheresis, mononuclear cells or
any enriched NK cell fraction have to be cultured in IL-2 for
several weeks to expand sufficient numbers of ANK cells. 
For clinical applications, only serum-free media can be
used. X-Vivo (BioWhittaker, Walkersville, Maryland, USA)
or XLCM medium (Haemosol , Etobicoke, Ontario,
Canada) will sufficiently support NK cell expansion [68],
which can be further enhanced by addition of autologous
s e rum [69]. Dulbecco’s modified Eagle’s/F12 medium sup-
plemented with 2-mercaptoethanol also supports NK cell
expansion, which, again, is optimized if human serum is
added [69]. 
Gas-permeable bags (ie, from American Fluoroseal Cor-
poration, Gaithersburg, Maryland, or Nexell, Irvine, Cali-
f o rnia) allow maintenance of a closed system during the
expansion procedure and during the subsequent preparation
for infusion into the patient. Stirrer flasks (available fro m
Techne, Princeton, New Jersey) or tissue culture flasks
(T175) are also suitable for expansion, although they repre-
sent an open system susceptible to microbological contami-
nation. Hollow fiber bioreactor systems [70] make it diffi-
cult to retrieve the cultured cells completely, there b y
reducing the final cell yield. More complex stirre r- t a n k
b i o reactors that control temperature and pH have been
exploited, but any advantage over bags has not been shown
[71].
When IL-2–expanded ANK cells are cry o p re s e rv e d ,
they lose their activity after thawing [72,73]. However, they
can regain activity when re c u l t u red in IL-2 for 48 hours,
although inconsistent reports range from full recovery [73-
75] to only partial recovery [72]. 
NK CELLS FOR EX VIVO PURGING 
Animal studies have shown that ANK cells can eff e c-
tively purge leukemia ex vivo. Long et al. [76] harvested BM
from normal Fischer rats, spiked it with increasing concen-
trations of syngeneic tumor cells (CRNK-16 leukemia), and
then incubated the mixture for 4 hours or 18 hours with
LAK cells generated from spleen cell preparation that had
been stimulated with IL-2. The mixture of BM/tumor/LAK
cells was then injected into untreated rats. Rats who
received LAK cell–purged BM had a significantly longer
survival at higher tumor doses compared to controls. When
the initial tumor cell contamination of the marrow was low,
the malignant cells were completely eliminated by prior LAK
cell purging. In the human system, a lymphoma cell line
(CA46) was used for spiking (10% contamination) of norm a l
BM. Elimination of the malignant clone was seen after it was
c o - c u l t u red with autologous LAK cells for 18 hours [77].
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The same study also showed that BM spiked with 5% auto-
logous ALL cells showed no evidence of heavy chain
rearrangement after being purged with LAK cells.
In vitro studies by Komatsu [13] used human BM–derived
allogeneic LAK cells to purge BCR/ABL-positive PBSC fro m
a patient with ALL. Using reverse-transcriptase polymerase
chain reaction, they showed that 7-day, IL-2–activated BM
cells can effectively eliminate BCR/ABL-positive cells fro m
PBSC when co-cultured for only 3 hours. These pre p a r a t i o n s
w e re then further selected for CD34 cells without compro m i s-
ing hematopoietic function. Similar observations were
re p o rted when an NK cell line (NK-92) was used for purg i n g
of K562 cells that had been mixed with normal PBMC. Eff e c-
tive purging occurred within 4 hours of co-culture [78]. 
The Vancouver group has transplanted autologous BM
that had been cultured in IL-2 for 8 days from patients with
AML in first remission [79]. Before clinical trials were initi-
ated, it was confirmed that IL-2 incubation of marrow or
PBPC generated high ANK activity and that this procedure
would not compromise hematopoietic stem cell function
[80], a result that was also reported by Aguila et al. [81]. In
v i t ro studies using neomycine-marked K562 cells had sug-
gested that significant purging of leukemic cells by ANK
o c c u rred within 8 days of culture of BM or PBMC with
I L -2 and that the purging effect could be augmented when a
combination of IL-2 and IL-12 was used [82]. The City of
Hope group has used high doses of IL-2 to purge BM for
24 hours prior to infusing it into patients conditioned for
transplant for leukemia [83]. 
Instead of using autologous NK cells either from BM
or mobilized PBSC for ex vivo purging of malignant cells,
allogeneic ANK cells from clonal lines can be expanded in
l a rge numbers and added to the preparation. Two MHC-
n o n restricted cell lines have been tested in pre c l i n i c a l
m o dels: the CD56+/CD3+ TALL-104 cell line [84] and the
CD56+/CD3– NK-92 cells [78,85]. The TALL-104 cell line,
which by definition is not an NK cell line, purges leukemic
cells from marrow after 18 hours of co-culture [84]. More
e ffective purging is achieved by NK-92 cells, which occurs
after just 4 hours of co-culture [85]. In several studies, NK-92
cells have been shown to display a broader antitumor cytotox-
icity than TALL-104 cells [86,87] possibly because of their
lack of expression of killer cell inhibitory (KIR) molecules
[88]. When NK-92 cells were co-cultured with BCR/ABL-
positive PBSC from CML patients, significant reduction of
the malignant clone after purging for 4 to 8 hours was docu-
mented by PCR [123].
NK/ANK CELLS FOR CELLULAR THERAPY
POSTTRANSPLANT?
P r eclinical Studies
In addition to direct cytolytic/apoptotic effects mediated
by the perforin/granzyme system, NK cells produce a num-
ber of cytokines that on their own (ie, TNF-α and IFN-γ) or
t h rough stimulation of other cells (IL-5: eosinophils; IFN:
monocytes) may exert a GvT effect. The contribution of NK
cells in the control of tumor growth is well established in
mice. Knockout mice for the transcriptional factor ETS-1,
which is essential for NK cell diff e rentiation, develop tumors
following injection of the NK-susceptible RMA-S cells [89].
Mice inoculated with human melanoma or leukemia can
achieve long-term survival when ANK cells are given [86,90]. 
Murine transplant models suggest that NK/ANK cells
do play an important role in GvT [91]. Zeis et al. [92] were
able to induce antileukemia effects without inducing
GVHD by infusing allogeneic donor–derived NK/ANK
cells after bone marrow transplant (BMT). Adoptive transfer
of activated NK cells from H2 (d) into H02 (b) mice had a
significant antitumor effect and prevented GVHD [55].
Other studies in mice have confirmed that NK cells fro m
allogeneic mismatched donors have antitumor effects, do
not cause GVHD, and are well tolerated [54,93]. 
C h e m o t h e r a p y - resistant human tumor targets can be
e ffectively lysed by IL-2–activated NK cells [83,86,94].
NK/LAK cells can induce apoptosis in K562 cells, which are
usually resistant to apoptosis because of BCR/ABL expres-
sion [95]. CML cells in particular seem to be targets for
NK/ANK-mediated lysis. In patients with CML, NK cell
c y t o t o x i c i t y, clonogenic potential, and ability to generate
ANK cells diminishes with pro g ression of the disease
[69,96,97]. Hauch et al. [98] have shown that the risk of
relapse after  allogeneic transplantation is reduced if
NK/ANK cells kill autologous CML cells in vitro. Jiang
et al. [99] re p o rted that patients who relapsed after allo-
geneic transplantation for CML had lower numbers of blood
NK cells compared with patients who remained in re m i s s i o n .
Clonal cell lines with NK cell activity that were established
f rom a patient with ALL after allogeneic T- c e l l – d e p l e t e d
BM transplantation effectively lysed pretransplant cry o p re-
s e rved leukemic blasts [100]. Furt h e rm o re, cytolytic NK cell
clones recognizing myeloid blasts could be generated fro m
patients who had received a haploidentical transplant [56].
Cytotoxic non-major histocompatibility complex–re s t r i c t e d
CD3+ cells that also carry the CD56+ antigen have been
described [101]. The Stanford group has shown that these
cells can be expanded in the presence of IFN-γ, IL-2, and
anti-CD3 [102]. These cytokine-induced killer (CIK) cells
can protect SCID mice from a lethal challenge with the
human lymphoma cell line SU-DHL-4 [103]. CIK cells fro m
patients with CML do not carry the Ph chromosome and
have been shown to control CML in SCID mice [104]. 
A u t o l o gous ANK Cells Generated Pr e - B M T
Lister et al. [105] obtained adherent NK cells fro m
patients with lymphoma prior to autologous stem cell trans-
plantation. Mononuclear cells collected by leukaphere s i s
(after priming with low-dose IL-2 for 6 days) were cultured
in IL-2 for 2 to 3 weeks and infused into the patient on day
2 after transplant. At the same time, IL-2 was initiated as
continuous infusion at 2 3 106 international units (IU)/m2
per day for 4 days followed by 3 3 1 05 I U / m2 per day for
3 months. No adverse short-term or long-term effects were
observed. Because this was a feasibility trial, no information
as to the efficacy of this approach is available. 
The studies by the Vancouver group used an 8-day co-
culture of BM or PBSC with IL-2 to achieve ex vivo purg-
ing and activated NK cells for infusion with stem cells [79].
The cytotoxic activity of the infused cells was maintained by
giving low doses of IL-2 posttransplant from day 0 to day 7.
Because engraftment with marrow alone was delayed, subse-
quent patients were transplanted with PBSC instead of BM,
95B B & M T
which resulted in prompt engraftment [106]. This adoptive
transfer approach had no significant side effects, although
fever and fatigue occurred in almost all patients at relatively
low doses of IL-2 (.5 3 1 06/ m2). Pre l i m i n a ry data are
encouraging in respect to disease-free survival [106]. How-
e v e r, as with many immunotherapy-based treatments in
stem cell transplantation, the challenge will be to show that
these more complex treatments do change patient outcome
for the better. 
Other investigators have attempted to expand the NK
cell pool by giving IL-2 after mobilizing chemotherapy,
along with hematopoietic growth factors [107]. Because
activated NK cells will die during the cryo-procedure, they
need to be restimulated with IL-2 before they are infused
into the patient.
A u t o l o gous ANK Cells Generated P o s t - B M T
Although IL-2 treatment with higher doses is poorly
tolerated early after transplant [108], low doses can be given
for a prolonged period of time. Soiffer et al. [109] adminis-
tered IL-2 by continuous infusion via an intravenous pump.
A gradual increase in the number of NK cells and their
function through day 90 was noted. In the study by Miller
et al. [110] in which IL-2 was given for 84 consecutive days,
NK-lymphocytosis occurred with a maximum at day 14. It
has been suggested that differences in the route of injection
(continuous intravenous versus subcutaneous) or in the IL-2
p reparation (Roche versus Amgen) may account for these
discrepant observations.
Benyunes et al. [111] collected mononuclear cells by
l e u k a p h e resis from patients with AML or NHL after autol-
ogous transplantation when engraftment had occurre d .
Patients were given IL-2 intravenously for 5 days prior to
l e u k a p h e resis and again after the ex vivo–generated LAK
cells had been reinfused. This maintenance dose of IL-2
was only about one third of the dose pre - l e u k a p h e resis and
was given for 9 days. Infusions of LAK cells were associated
with fevers, chills, and dyspnea in most patients. In addition
to the side effects from high-dose IL-2, thro m b o c y t o p e n i a
(especially in patients after BM transplantation for AML)
was frequently induced by the repeated leukaphere s e s .
Although the survival data for these groups of patients look
favorable, this particular form of consolidative immuno-
therapy with IL-2 and LAK cells re q u i res hospitalization
and is costly. 
A l l o geneic ANK Cells
In some patients with cancer, NK cells cannot be suf-
ficiently activated, which has been shown for patients with
H o d g k i n ’s disease [105], melanoma, and renal cell cancer
[112].  Allogeneic NK cells obtained either from the
p a t i e n t ’s BM or PBSC donor, or even from a haploidenti-
cal relative, could potentially be more useful in these
cases. Such an approach re q u i res treatment of these
donors with IL-2 followed by leukapheresis. Repeated
infusion of LAK cells from a pool of unrelated donors did
not cause side effects in cancer patients [113]. The investi-
gators mixed blood from 10 to 20 persons and incubated
the buffy coat with IL-2 for several weeks. Although anti-
HLA antibodies were generated in the recipients, ex vivo
mixing experiments suggested that they apparently did not
i n t e rf e re with LAK cell cytotoxicity. Some responses were
re p o rted to have occurred, although no detailed inform a-
tion is available [113].
A patient who relapsed after allogeneic BMT for AML
was given an infusion of LAK cells, which had been gener-
ated from the patient’s (donor derived) blood mononuclear
cells [114]. On the fourth day of IL-2 treatment and LAK
infusions, he developed a generalized rash that was histolog-
ically suggestive of acute GVHD (stage II). Of note is that
the molecular analysis confirmed that the “autologous” LAK
cells were of donor origin. The patient achieved a remission
that lasted 9 months, 2 months longer than the first remis-
sion after the allo-transplant.
NK/ANK Cells From Cell Lines
Instead of infusing autologous or allogeneic blood
NK/ANK cells, it may even be more effective and easier to
generate cells from clonal cell lines on a large-scale basis for
use in treatment. Although several human NK/ANK cell
lines have been described [115-119], only 2 have been
shown to have broad and consistently high cytolytic activity
against malignant target cells. The cytotoxic TALL-104 cell
line is T-cell derived and has demonstrated in vivo activity
against gliomas in dogs [120]. Phase I trials in patients with
advanced cancer are ongoing. NK-92 has broader and
higher cytolytic activity than TALL-104 [87; and Y. Ya n ,
unpublished observations]. The Sloan-Kettering group has
shown that outcome in SCID mice injected with human
leukemia is greatly prolonged if these animals are tre a t e d
with NK-92 cells [86]. Similar results were obtained in
SCID mice inoculated with human melanoma cell lines [ 9 0 ] .
Although most malignant targets are sensitive to NK-9 2
killing, some are not. Those targets may be converted to
sensitivity by pretreatment with cytokines (such as TNF-α),
which induces adhesion molecules and other surface mole-
cules on target cells [4].
NK-92 cells have recently been transfected with retrovi-
ral- [121] and plasmid-based [122] gene constructs carrying
the IL-2 cDNA to make their growth IL-2 independent.
The cell line is radiosensitive, and low doses of radiation
(0.5-1 Gy) suppress their clonogenic potential without
diminishing its cytolytic activity [85,86]. The first patients
with advanced cancer have received NK-92 cell infusions as
part of a phase I trial (T. Tonn, unpublished observations).
Even repeated infusions with NK-92 cells were well tolerated.
The cell line can be expanded under serum-free conditions
within a few days of culture. If safety and efficacy studies are
completed, it is hoped that NK-92 cells could become part
of the posttransplant management for patients after autolo-
gous or allogeneic transplantation. 
Clearly, as we continue to learn more about the biology
of NK cells, especially their interaction with other cells, we
will be able to make better use of their potential to exert
antitumor effects, particularly in the context of hemato-
poietic stem cell transplantation. 
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